MARKET

VRDN

VRDN

Viridian Therapeutics Inc
NASDAQ
30.92
-0.62
-1.97%
Opening 11:35 12/30 EST
OPEN
31.57
PREV CLOSE
31.54
HIGH
31.79
LOW
30.92
VOLUME
258.07K
TURNOVER
--
52 WEEK HIGH
34.04
52 WEEK LOW
9.90
MARKET CAP
2.95B
P/E (TTM)
-8.3098
1D
5D
1M
3M
1Y
5Y
1D
My Market Outlook For 2026: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
Seeking Alpha · 1d ago
Weekly Report: what happened at VRDN last week (1222-1226)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST)
TipRanks · 12/23 12:30
Viridian Therapeutics Is Maintained at Buy by Needham
Dow Jones · 12/23 10:56
Viridian Therapeutics Price Target Raised to $42.00/Share From $34.00 by Needham
Dow Jones · 12/23 10:56
Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $42
Benzinga · 12/23 10:46
Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating
TipRanks · 12/23 10:45
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Sanofi (OtherSNYNF)
TipRanks · 12/23 10:40
More
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Webull offers Viridian Therapeutics Inc stock information, including NASDAQ: VRDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRDN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRDN stock methods without spending real money on the virtual paper trading platform.